MedCity News
4 takeaways from FDA’s emergency vaccine reviews
What lessons can future Covid vaccine candidates take from the FDA’s response to Pfizer and Moderna’s study data?
Shares0
After a grim and deadly year, and just in time for the holiday season, Americans finally have reason to hope.
This week, the U.S. government began delivering the first 2.9 million doses of BioNTech and Pfizer’s vaccine, with 20 million to be administered by the end of December. Last week, the U.S. doubled its initial August order for 100 million doses of Moderna’s offering. The federal government is also negotiating a new deal with Pfizer to take delivery of more of its vaccine in the spring.
Moderna files for U.S. vaccine authorization, will seek EU nod Healthcare & Pharma Michael Erman (Reuters) - Moderna Inc said on Monday it has applied for U.S. emergency authorization for its COVID-19 vaccine after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns.
FILE PHOTO: Vials with a sticker reading, COVID-19 / Coronavirus vaccine / Injection only and a medical syringe are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
FILE PHOTO: Moderna s logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo